 
			
			
		 
			
			
		 
                                
                                 
                                
                                
                                    Structure of Acalabrutinib
                                    
                                    
CAS No.: 1420477-60-6
                                    
                                
 
                                 
                            *Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
 
                            The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Acalabrutinib is a second-generation, selective and irreversible inhibitor of BTK (Bruton's tyrosine kinase) with an IC50 of 3 nM and EC50 of 8 nM in a human whole-blood CD69 B cell activation assay. Acalabrutinib has improved pharmacologic features, including favorable plasma exposure, rapid oral absorption, a short half-life, and the absence of irreversible targeting to alternative kinases.
Synonyms: ACP-196
 
                
        				4.5
        				
        					 
        					 
        					 
        					 
        					 *For Research Use Only !
        				
        				*For Research Use Only !
        			
Change View
| Size | Price | VIP Price | DE Stock US Stock | Asia Stock Global Stock | In Stock | 
| {[ item.pr_size ]} | Inquiry {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]}{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + | 
Please Login or Create an Account to: See VIP prices and availability
                                        
                                            Asia Stock: Ship in 3-5 business days
                                        
                                        
                                            EU Stock: ship in 0-1 business day
                                            
Global Stock: ship in 5-7 days
                                        
                                        
                                            US Stock: ship in 0-1 business day
                                            
Global Stock: ship in 5-7 days
                                        
                                    
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
                                        
                                            Asia Stock: Ship in 3-5 business days
                                        
                                        
                                            EU Stock: ship in 0-1 business day
                                            
Global Stock: ship in 5-7 days
                                        
                                        
                                            US Stock: ship in 0-1 business day
                                            
Global Stock: ship in 5-7 days
                                        
                                    
Search for reports by entering the product batch number.
    							Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
    							Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
    							Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
    							Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
    							Batch number can be found on the product's label following the word 'Batch'.
Joel Rüegger ; Berend Gagestein ; Antonius P. A. Janssen ; Alexandra Valeanu ; Alger Lazo Mori ; Marielle van der Peet , et al.
Abstract: The human genome encodes 518 protein kinases that are pivotal for drug discovery in various therapeutic areas such as cancer and autoimmune disorders. The majority of kinase inhibitors target the conserved ATP-binding pocket, making it difficult to develop selective inhibitors. To characterize and prioritize kinase-inhibiting drug candidates, efficient methods are desired to determine target engagement across the cellular kinome. In this study, we present CellEKT (Cellular Endogenous Kinase Targeting), an optimized and robust chemical proteomics platform for investigating cellular target engagement of endogenously expressed kinases using the sulfonyl fluoride-based probe XO44 and two new probes ALX005 and ALX011. The optimized workflow enabled the determination of the kinome interaction landscape of covalent and non-covalent drugs across over 300 kinases, expressed as half maximum inhibitory concentration (IC50), which were validated using distinct platforms like phosphoproteomics and NanoBRET. With CellEKT, target engagement profiles were linked to their substrate space. CellEKT has the ability to decrypt drug actions and to guide the discovery and development of drugs.
Show More >
Keywords: CellEKT ; cellular target engagement ; endogenous kinome profiling ; XO44 ; IC50 ; drug selectivity ; broadspectrum kinase probes ; chemical proteomics ; ABPP
Show More >
 
                        | CAS No. : | 1420477-60-6 | 
| Formula : | C26H23N7O2 | 
| M.W : | 465.51 | 
| SMILES Code : | O=C(NC1=NC=CC=C1)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]5N(C(C#CC)=O)CCC5)=N3)C=C2 | 
| Synonyms : | 
                                ACP-196
                             | 
| MDL No. : | MFCD29472294 | 
| InChI Key : | WDENQIQQYWYTPO-IBGZPJMESA-N | 
| Pubchem ID : | 71226662 | 
| GHS Pictogram: |   | 
| Signal Word: | Warning | 
| Hazard Statements: | H373 | 
| Precautionary Statements: | P260-P314-P501 | 
| Target | 
 | 
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations | 
| NCT04548648 | Central Nervous System Lymphom... More >>a Less << | PHASE2 | RECRUITING | 2033-02-22 | Moffit Cancer Center, Tampa, F... More >>lorida, 33612, United States|Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, 27599, United States|Wake Forest University,The Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, 27157-1096, United States Less << | 
| NCT02112526 | Activated B-cell Diffuse Large... More >> B-Cell Lymphoma (ABC DLBCL) Less << | PHASE1 | COMPLETED | 2024-10-04 | Research Site, Los Angeles, Ca... More >>lifornia, 90095, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, New York, New York, 10021, United States|Research Site, Columbus, Ohio, 43210, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Leicester, LE1 7RH, United Kingdom|Research Site, Plymouth, PL6 8DH, United Kingdom Less << | 
| NCT05557695 | Chronic Lymphocytic Leukemia, ... More >>CLL Less << | RECRUITING | 2026-04-01 | Research Site, Aylesbury, Unit... More >>ed Kingdom|Research Site, Bath, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Conrnwall, United Kingdom|Research Site, Dartford, United Kingdom|Research Site, Derby, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Dorset, United Kingdom|Research Site, Eastbourne, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Lincoln, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Mid Yorkshire, United Kingdom|Research Site, Middlesborough, United Kingdom|Research Site, Newcastle, United Kingdom|Research Site, North Shields, United Kingdom|Research Site, Norwich, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Stockton on Tees, United Kingdom|Research Site, Stoke on Trent, United Kingdom|Research Site, Wigan, United Kingdom Less << | |
| NCT02029443 | Chronic Lymphocytic Leukemia|S... More >>mall Lymphocytic Lymphoma|Richter's Syndrome|Prolymphocytic Leukemia Less << | PHASE1|PHASE2 | ACTIVE_NOT_RECRUITING | 2027-09-06 | Research Site, Boston, Massach... More >>usetts, 2215, United States|Research Site, New Hyde Park, New York, 11042, United States|Research Site, New York, New York, 10021, United States|Research Site, Columbus, Ohio, 43210, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Salt Lake City, Utah, 84112, United States|Research Site, Seattle, Washington, 98122, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Milano, 20132, Italy|Research Site, Leeds, LS9 7TF, United Kingdom|Research Site, London, SE5 9RS, United Kingdom|Research Site, Oxford, OX3 7LE, United Kingdom Less << | 
| NCT04497948 | COVID-19 | PHASE1 | TERMINATED | 2020-11-18 | Research Site, Porto Alegre, 9... More >>0035-003, Brazil|Research Site, Ribeir?o Preto, 14051-140, Brazil|Research Site, Sao Paulo, 01321-001, Brazil|Research Site, Sao Paulo, 01323-903, Brazil Less << | 
| NCT05256641 | Diffuse Large B-Cell Lymphoma|... More >>High-grade B-cell Lymphoma|Transformed Lymphoma|Secondary Central Nervous System Lymphoma Less << | PHASE1|PHASE2 | RECRUITING | 2026-10-01 | UCLA / Jonsson Comprehensive C... More >>ancer Center, Los Angeles, California, 90095, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States|University of Oklahoma, Oklahoma City, Oklahoma, 73190, United States Less << | 
| NCT05038904 | Food Allergy|Food Allergy Pean... More >>ut Less << | PHASE2 | COMPLETED | 2022-12-31 | Johns Hopkins Bayview Medical ... More >>Center, Baltimore, Maryland, 21224, United States Less << | 
| NCT03932331 | Phase I: Relapsed or Refractor... More >>y B-cell Malignancies|Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma|Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia Less << | PHASE1|PHASE2 | ACTIVE_NOT_RECRUITING | 2023-12-29 | Research Site, Beijing, 100044... More >>, China|Research Site, Beijing, 100142, China|Research Site, Beijing, 100191, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410008, China|Research Site, Changzhou, 272100, China|Research Site, Chengdu, 610041, China|Research Site, Fuzhou, China|Research Site, Haikou, 570311, China|Research Site, Hangzhou, 310003, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150049, China|Research Site, Hefei, 230031, China|Research Site, Hohhot, 10050, China|Research Site, Nanchang, 330006, China|Research Site, Nanjing, 210029, China|Research Site, Shanghai, 200032, China|Research Site, Suzhou, 215006, China|Research Site, Tianjin, 300020, China|Research Site, Tianjin, 300060, China|Research Site, Urumqi, 830054, China|Research Site, Xining, 810007, China|Research Site, Zhengzhou, 450008, China Less << | 
| NCT02586857 | Glioblastoma Multiforme | PHASE1|PHASE2 | ACTIVE_NOT_RECRUITING | 2026-04-01 | Research Site, Los Angeles, Ca... More >>lifornia, 90095-1769, United States|Research Site, Palo Alto, California, 94304, United States|Research Site, Boston, Massachusetts, 02114, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Boston, Massachusetts, 2215, United States|Research Site, New York, New York, 10021, United States|Research Site, Vancouver, Washington, 98684, United States Less << | 
| NCT04402138 | Mantle Cell Lymphoma | PHASE2 | COMPLETED | 2024-04-05 | Colorado Blood Cancer Institut... More >>e, Denver, Colorado, 80218, United States|Tulane University, Office of Clinical Research, New Orleans, Louisiana, 70112, United States|HCA Midwest, Kansas City, Missouri, 64132, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States Less << | 
| NCT04906902 | Central Nervous System Lymphom... More >>a|Refractory Central Nervous System Lymphoma|Recurrent Central Nervous System Lymphoma Less << | PHASE1|PHASE2 | RECRUITING | 2027-01-31 | Brigham and Women's Hospital, ... More >>Boston, Massachusetts, 02115, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less << | 
| NCT04660045 | Chronic Lymphocytic Leukemia|C... More >>LL/SLL Less << | PHASE2 | WITHDRAWN | 2025-06-26 | Weill Cornell Medicine, New Yo... More >>rk, New York, 10065, United States Less << | 
| NCT04346199 | COVID-19 | PHASE2 | COMPLETED | 2020-11-17 | Research Site, Ciudad de Bueno... More >>s Aires, 1221, Argentina|Research Site, Ciudad de Buenos Aires, C1180AAX, Argentina|Research Site, Monte Grande, B1842, Argentina|Research Site, Ramos Mejía, B1704, Argentina|Research Site, Botucatu, 18618-687, Brazil|Research Site, Brasillia, 72145-450, Brazil|Research Site, Florianópolis, 88036-800, Brazil|Research Site, Porto Alegre, 90035-903, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Ribeir?o Preto, 14051-140, Brazil|Research Site, Salvador, 40110-060, Brazil|Research Site, Sao Bernardo do Campo, 09715090, Brazil|Research Site, Sao Paulo, 01327-001, Brazil|Research Site, Sao Paulo, 04004-030, Brazil|Research Site, S?o Paulo, 01308-050, Brazil|Research Site, Curico, 3341643, Chile|Research Site, Santiago, 7500692, Chile|Research Site, Talca, 3460001, Chile|Research Site, Villejuif Cedex, 94805, France|Research Site, Frankfurt, 60590, Germany|Research Site, Gauting, 82131, Germany|Research Site, K?ln, 50937, Germany|Research Site, Bangalore, 560002, India|Research Site, New Delhi, 110017, India|Research Site, Milano, 20132, Italy|Research Site, Roma, 00168, Italy|Research Site, Shinjuku-ku, 162-8655, Japan|Research Site, D.F, 14050, Mexico|Research Site, Monterrey, 64461, Mexico|Research Site, México, 03103, Mexico|Research Site, Lima, 15324, Peru|Research Site, Lima, LIMA 11, Peru|Research Site, Lima, LIMA 1, Peru|Research Site, Warszawa, 02-507, Poland|Research Site, Warszawa, 04-141, Poland|Research Site, Moscow, 111539, Russian Federation|Research Site, Moscow, 119992, Russian Federation|Research Site, Moscow, 123182, Russian Federation|Research Site, Moscow, 143442, Russian Federation|Research Site, Murmansk, 183047, Russian Federation|Research Site, Cape Town, 7500, South Africa|Research Site, George, 6529, South Africa|Research Site, Johannesburg, 1827, South Africa|Research Site, Johannesburg, 2193, South Africa|Research Site, Pretoria, 0157, South Africa|Research Site, Ankara, 06800, Turkey|Research Site, Bakirkoy, 34147, Turkey|Research Site, Istanbul, 34214, Turkey|Research Site, Istanbul, Turkey|Research Site, Umraniye, 34760, Turkey Less << | 
| NCT04008706 | Chronic Lymphocytic Leukemia | PHASE3 | ACTIVE_NOT_RECRUITING | 2025-09-01 | Research Site, Chandler, Arizo... More >>na, 85224, United States|Research Site, Long Beach, California, 90806, United States|Research Site, Redlands, California, 92373, United States|Research Site, Whittier, California, 90603, United States|Research Site, Fort Myers, Florida, 33908, United States|Research Site, Jacksonville, Florida, 32256, United States|Research Site, Saint Petersburg, Florida, 33705, United States|Research Site, Marietta, Georgia, 30060, United States|Research Site, Normal, Illinois, 61761, United States|Research Site, Peoria, Illinois, 61615, United States|Research Site, Fort Wayne, Indiana, 46845, United States|Research Site, Indianapolis, Indiana, 46260, United States|Research Site, Shreveport, Louisiana, 71105, United States|Research Site, Saint Cloud, Minnesota, 56303, United States|Research Site, Kansas City, Missouri, 64132, United States|Research Site, Bethlehem, Pennsylvania, 18015, United States|Research Site, Chattanooga, Tennessee, 37404, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Dallas, Texas, 75235, United States|Research Site, Adelaide, 5000, Australia|Research Site, Bedford Park, 5042, Australia|Research Site, Clayton, 3168, Australia|Research Site, Fitzroy, 3065, Australia|Research Site, Nedlands, 6009, Australia|Research Site, South Brisbane, 4101, Australia|Research Site, Belo Horizonte, 30130-100, Brazil|Research Site, Curitiba, 81520-060, Brazil|Research Site, Goiania, 74605-020, Brazil|Research Site, Porto Alegre, 90035-003, Brazil|Research Site, Porto Alegre, 90110-270, Brazil|Research Site, Ribeir?o Preto, 14048-900, Brazil|Research Site, Sao Paulo, 01236-030, Brazil|Research Site, S?o Paulo, 01323-900, Brazil|Research Site, Calgary, Alberta, T2N 4N2, Canada|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Victoria, British Columbia, V8R 6V5, Canada|Research Site, Winnipeg, Manitoba, R3E 0V9, Canada|Research Site, Halifax, Nova Scotia, B3H 1V7, Canada|Research Site, Brampton, Ontario, L6R 3J7, Canada|Research Site, Newmarket, Ontario, L3Y 2P9, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Aalborg, 9100, Denmark|Research Site, Aarhus, 8200, Denmark|Research Site, Herlev, 2730, Denmark|Research Site, K?benhavn ?, 2100, Denmark|Research Site, Odense, 5000, Denmark|Research Site, Roskilde, 4000, Denmark|Research Site, Hus, 00029, Finland|Research Site, Kuopio, 70210, Finland|Research Site, Tampere, 33521, Finland|Research Site, Bordeaux, 33076, France|Research Site, Brest, 29609, France|Research Site, Limoges, 87042, France|Research Site, Reims, 51092, France|Research Site, Tours, 37000, France|Research Site, Vandoeuvre-Les-Nancy, 54511, France|Research Site, Bayern, 63739, Germany|Research Site, Essen, 45147, Germany|Research Site, Homburg, 66421, Germany|Research Site, Porta Westfalica, 32457, Germany|Research Site, Schw?bisch Hall, 74523, Germany|Research Site, Catanzaro, 88100, Italy|Research Site, Milano, 20122, Italy|Research Site, Roma, 00161, Italy|Research Site, Roma, 00168, Italy|Research Site, Siena, 53100, Italy|Research Site, Busan, 49241, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Seoul, 135-710, Korea, Republic of|Research Site, Ulsan, 44033, Korea, Republic of|Research Site, Arnhem, 6815 AD, Netherlands|Research Site, Dordrecht, 3318 AT, Netherlands|Research Site, Utrecht, 3584 CX, Netherlands|Research Site, Bergen, 5053, Norway|Research Site, Oslo, 1478, Norway|Research Site, Trondheim, 7006, Norway|Research Site, Moscow, 115478, Russian Federation|Research Site, Moscow, 125167, Russian Federation|Research Site, Moscow, 125284, Russian Federation|Research Site, Nizhny Novgorod, 603126, Russian Federation|Research Site, Petrozavodsk, 185019, Russian Federation|Research Site, Saint Petersburg, 191024, Russian Federation|Research Site, Saint Petersburg, 194291, Russian Federation|Research Site, Saint Petersburg, 197341, Russian Federation|Research Site, Saint-Petersburg, 197110, Russian Federation|Research Site, Smolensk, 214015, Russian Federation|Research Site, Smolensk, 214031, Russian Federation|Research Site, St. Petersburg, 197022, Russian Federation|Research Site, St. Petersburg, 197341, Russian Federation|Research Site, Syktyvkar, 167904, Russian Federation|Research Site, Barcelona, 08036, Spain|Research Site, Madrid, 28006, Spain|Research Site, Madrid, 28041, Spain|Research Site, Marbella, 29603, Spain|Research Site, Ourense, 32005, Spain|Research Site, Oviedo, 33011, Spain|Research Site, Vitoria, 01009, Spain|Research Site, Zaragoza, 50009, Spain|Research Site, Lule?, 97180, Sweden|Research Site, Lund, 221 85, Sweden|Research Site, Uppsala, 75185, Sweden|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan, 704, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 11217, Taiwan|Research Site, Liverpool, L7 8XP, United Kingdom|Research Site, Newmarket, CB8 7XN, United Kingdom Less << | 
| NCT04657094 | Autoimmune Hemolytic Anemia|Ch... More >>ronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Warm Antibody Autoimmune Hemolytic Anemia Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2024-12-30 | City of Hope Medical Center, D... More >>uarte, California, 91010, United States Less << | 
| NCT04189757 | Mantle Cell Lymphoma | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-06-30 | M D Anderson Cancer Center, Ho... More >>uston, Texas, 77030, United States Less << | 
| NCT04867941 | Hepatic Insufficiency | PHASE1 | COMPLETED | 2015-02-02 | Research Site, Miami, Florida,... More >> 33136, United States|Research Site, Orlando, Florida, 32809, United States|Research Site, Knoxville, Tennessee, 37920, United States Less << | 
| NCT04380688 | COVID-19 | PHASE2 | COMPLETED | 2020-11-16 | Research Site, Anniston, Alaba... More >>ma, 36207, United States|Research Site, Mobile, Alabama, 36604, United States|Research Site, Escondido, California, 92029, United States|Research Site, Fullerton, California, 92835, United States|Research Site, Glendale, California, 91206, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, New Haven, Connecticut, 06519, United States|Research Site, Washington, District of Columbia, 20010, United States|Research Site, Fort Lauderdale, Florida, 33308, United States|Research Site, Jacksonville, Florida, 32207, United States|Research Site, Jacksonville, Florida, 32209, United States|Research Site, Loxahatchee Groves, Florida, 33470, United States|Research Site, Fort Wayne, Indiana, 46804, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, Annapolis, Maryland, 21401, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Bethesda, Maryland, 20889, United States|Research Site, Bethesda, Maryland, 20892-1374, United States|Research Site, Silver Spring, Maryland, 20910, United States|Research Site, Hackensack, New Jersey, 07601, United States|Research Site, Albany, New York, 12208, United States|Research Site, Bronx, New York, 10467, United States|Research Site, Buffalo, New York, 14263, United States|Research Site, New York, New York, 10029, United States|Research Site, Philadelphia, Pennsylvania, 19140, United States|Research Site, Nashville, Tennessee, 38120, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Houston, Texas, 77090, United States|Research Site, Tyler, Texas, 75701, United States|Research Site, Richmond, Virginia, 23298, United States|Research Site, Renton, Washington, 98055, United States Less << | 
| NCT04604067 | Diffuse Large B-cell Lymphoma | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-12-30 | Ospedale Papa Giovanni XXIII, ... More >>Bergamo, 24127, Italy|Azienda Ospedaliera Universitaria Maggiore della Carita di Novara, Novara, 20503, Italy|Policlinico Agostino Gemelli, Roma, 00168, Italy|Kantonsspital Aarau, Aarau, CH-5001, Switzerland|Kantonsspital Baden (Baden/Brugg), Baden, 5404, Switzerland|St. Claraspital, Basel, 4058, Switzerland|Istituto Oncologico della Svizzera Italiana, Bellinzona, 6500, Switzerland|Inselspital, Bern, Bern, CH-3010, Switzerland|Kantonsspital Graubünden, Chur, 7000, Switzerland|Hopital Fribourgeois, Fribourg, 1708, Switzerland|Hopitaux Universitaire de Genève (HUG), Geneva, 1211, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, CH-1011, Switzerland|Kantonsspital Luzern, Luzerne, CH-6000, Switzerland|Réseau Hospitalier Neuchatelois (RHNe), Neuchatel, 2000, Switzerland|Kantonsspital Olten, Olten, CH-4600, Switzerland|Kantonsspital St. Gallen, St. Gallen, 9007, Switzerland|Kantonsspital Winterthur, Winterthur, 8401, Switzerland|City Hospital Triemli, Zurich, CH-8063, Switzerland|Universit?tsSpital Zürich, Zürich, 8091, Switzerland Less << | 
| NCT04094142 | Non-hodgkin Lymphoma,B Cell | PHASE2 | COMPLETED | 2022-05-15 | Seoul National University Hosp... More >>ital, Seoul, 03080, Korea, Republic of Less << | 
Tags: Acalabrutinib | ACP-196 | ACP196 | ACP 196 | Btk inhibitor | Bruton tyrosine kinase | irreversible | ERK | IKB | Cys481 | lymphocytic | leukemia | PLCγ2 | azide-alkyne cycloaddition | 1420477-60-6
| Precautionary Statements-General | |
| Code | Phrase | 
| P101 | If medical advice is needed,have product container or label at hand. | 
| P102 | Keep out of reach of children. | 
| P103 | Read label before use | 
| Prevention | |
| Code | Phrase | 
| P201 | Obtain special instructions before use. | 
| P202 | Do not handle until all safety precautions have been read and understood. | 
| P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. | 
| P211 | Do not spray on an open flame or other ignition source. | 
| P220 | Keep/Store away from clothing/combustible materials. | 
| P221 | Take any precaution to avoid mixing with combustibles | 
| P222 | Do not allow contact with air. | 
| P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. | 
| P230 | Keep wetted | 
| P231 | Handle under inert gas. | 
| P232 | Protect from moisture. | 
| P233 | Keep container tightly closed. | 
| P234 | Keep only in original container. | 
| P235 | Keep cool | 
| P240 | Ground/bond container and receiving equipment. | 
| P241 | Use explosion-proof electrical/ventilating/lighting/equipment. | 
| P242 | Use only non-sparking tools. | 
| P243 | Take precautionary measures against static discharge. | 
| P244 | Keep reduction valves free from grease and oil. | 
| P250 | Do not subject to grinding/shock/friction. | 
| P251 | Pressurized container: Do not pierce or burn, even after use. | 
| P260 | Do not breathe dust/fume/gas/mist/vapours/spray. | 
| P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. | 
| P262 | Do not get in eyes, on skin, or on clothing. | 
| P263 | Avoid contact during pregnancy/while nursing. | 
| P264 | Wash hands thoroughly after handling. | 
| P265 | Wash skin thouroughly after handling. | 
| P270 | Do not eat, drink or smoke when using this product. | 
| P271 | Use only outdoors or in a well-ventilated area. | 
| P272 | Contaminated work clothing should not be allowed out of the workplace. | 
| P273 | Avoid release to the environment. | 
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. | 
| P281 | Use personal protective equipment as required. | 
| P282 | Wear cold insulating gloves/face shield/eye protection. | 
| P283 | Wear fire/flame resistant/retardant clothing. | 
| P284 | Wear respiratory protection. | 
| P285 | In case of inadequate ventilation wear respiratory protection. | 
| P231 + P232 | Handle under inert gas. Protect from moisture. | 
| P235 + P410 | Keep cool. Protect from sunlight. | 
| Response | |
| Code | Phrase | 
| P301 | IF SWALLOWED: | 
| P304 | IF INHALED: | 
| P305 | IF IN EYES: | 
| P306 | IF ON CLOTHING: | 
| P307 | IF exposed: | 
| P308 | IF exposed or concerned: | 
| P309 | IF exposed or if you feel unwell: | 
| P310 | Immediately call a POISON CENTER or doctor/physician. | 
| P311 | Call a POISON CENTER or doctor/physician. | 
| P312 | Call a POISON CENTER or doctor/physician if you feel unwell. | 
| P313 | Get medical advice/attention. | 
| P314 | Get medical advice/attention if you feel unwell. | 
| P315 | Get immediate medical advice/attention. | 
| P320 | |
| P302 + P352 | IF ON SKIN: wash with plenty of soap and water. | 
| P321 | |
| P322 | |
| P330 | Rinse mouth. | 
| P331 | Do NOT induce vomiting. | 
| P332 | IF SKIN irritation occurs: | 
| P333 | If skin irritation or rash occurs: | 
| P334 | Immerse in cool water/wrap n wet bandages. | 
| P335 | Brush off loose particles from skin. | 
| P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. | 
| P337 | If eye irritation persists: | 
| P338 | Remove contact lenses, if present and easy to do. Continue rinsing. | 
| P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. | 
| P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. | 
| P342 | If experiencing respiratory symptoms: | 
| P350 | Gently wash with plenty of soap and water. | 
| P351 | Rinse cautiously with water for several minutes. | 
| P352 | Wash with plenty of soap and water. | 
| P353 | Rinse skin with water/shower. | 
| P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. | 
| P361 | Remove/Take off immediately all contaminated clothing. | 
| P362 | Take off contaminated clothing and wash before reuse. | 
| P363 | Wash contaminated clothing before reuse. | 
| P370 | In case of fire: | 
| P371 | In case of major fire and large quantities: | 
| P372 | Explosion risk in case of fire. | 
| P373 | DO NOT fight fire when fire reaches explosives. | 
| P374 | Fight fire with normal precautions from a reasonable distance. | 
| P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 | 
| P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. | 
| P378 | |
| P380 | Evacuate area. | 
| P381 | Eliminate all ignition sources if safe to do so. | 
| P390 | Absorb spillage to prevent material damage. | 
| P391 | Collect spillage. Hazardous to the aquatic environment | 
| P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. | 
| P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. | 
| P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. | 
| P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. | 
| P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. | 
| P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. | 
| P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. | 
| P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. | 
| P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. | 
| P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. | 
| P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. | 
| P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. | 
| P308 + P313 | IF exposed or concerned: Get medical advice/attention. | 
| P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. | 
| P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. | 
| P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. | 
| P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. | 
| P337 + P313 | IF eye irritation persists: Get medical advice/attention. | 
| P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. | 
| P370 + P376 | In case of fire: Stop leak if safe to Do so. | 
| P370 + P378 | In case of fire: | 
| P370 + P380 | In case of fire: Evacuate area. | 
| P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. | 
| P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. | 
| Storage | |
| Code | Phrase | 
| P401 | |
| P402 | Store in a dry place. | 
| P403 | Store in a well-ventilated place. | 
| P404 | Store in a closed container. | 
| P405 | Store locked up. | 
| P406 | Store in corrosive resistant/ container with a resistant inner liner. | 
| P407 | Maintain air gap between stacks/pallets. | 
| P410 | Protect from sunlight. | 
| P411 | |
| P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. | 
| P413 | |
| P420 | Store away from other materials. | 
| P422 | |
| P402 + P404 | Store in a dry place. Store in a closed container. | 
| P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. | 
| P403 + P235 | Store in a well-ventilated place. Keep cool. | 
| P410 + P403 | Protect from sunlight. Store in a well-ventilated place. | 
| P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. | 
| P411 + P235 | Keep cool. | 
| Disposal | |
| Code | Phrase | 
| P501 | Dispose of contents/container to ... | 
| P502 | Refer to manufacturer/supplier for information on recovery/recycling | 
| Physical hazards | |
| Code | Phrase | 
| H200 | Unstable explosive | 
| H201 | Explosive; mass explosion hazard | 
| H202 | Explosive; severe projection hazard | 
| H203 | Explosive; fire, blast or projection hazard | 
| H204 | Fire or projection hazard | 
| H205 | May mass explode in fire | 
| H220 | Extremely flammable gas | 
| H221 | Flammable gas | 
| H222 | Extremely flammable aerosol | 
| H223 | Flammable aerosol | 
| H224 | Extremely flammable liquid and vapour | 
| H225 | Highly flammable liquid and vapour | 
| H226 | Flammable liquid and vapour | 
| H227 | Combustible liquid | 
| H228 | Flammable solid | 
| H229 | Pressurized container: may burst if heated | 
| H230 | May react explosively even in the absence of air | 
| H231 | May react explosively even in the absence of air at elevated pressure and/or temperature | 
| H240 | Heating may cause an explosion | 
| H241 | Heating may cause a fire or explosion | 
| H242 | Heating may cause a fire | 
| H250 | Catches fire spontaneously if exposed to air | 
| H251 | Self-heating; may catch fire | 
| H252 | Self-heating in large quantities; may catch fire | 
| H260 | In contact with water releases flammable gases which may ignite spontaneously | 
| H261 | In contact with water releases flammable gas | 
| H270 | May cause or intensify fire; oxidizer | 
| H271 | May cause fire or explosion; strong oxidizer | 
| H272 | May intensify fire; oxidizer | 
| H280 | Contains gas under pressure; may explode if heated | 
| H281 | Contains refrigerated gas; may cause cryogenic burns or injury | 
| H290 | May be corrosive to metals | 
| Health hazards | |
| Code | Phrase | 
| H300 | Fatal if swallowed | 
| H301 | Toxic if swallowed | 
| H302 | Harmful if swallowed | 
| H303 | May be harmful if swallowed | 
| H304 | May be fatal if swallowed and enters airways | 
| H305 | May be harmful if swallowed and enters airways | 
| H310 | Fatal in contact with skin | 
| H311 | Toxic in contact with skin | 
| H312 | Harmful in contact with skin | 
| H313 | May be harmful in contact with skin | 
| H314 | Causes severe skin burns and eye damage | 
| H315 | Causes skin irritation | 
| H316 | Causes mild skin irritation | 
| H317 | May cause an allergic skin reaction | 
| H318 | Causes serious eye damage | 
| H319 | Causes serious eye irritation | 
| H320 | Causes eye irritation | 
| H330 | Fatal if inhaled | 
| H331 | Toxic if inhaled | 
| H332 | Harmful if inhaled | 
| H333 | May be harmful if inhaled | 
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled | 
| H335 | May cause respiratory irritation | 
| H336 | May cause drowsiness or dizziness | 
| H340 | May cause genetic defects | 
| H341 | Suspected of causing genetic defects | 
| H350 | May cause cancer | 
| H351 | Suspected of causing cancer | 
| H360 | May damage fertility or the unborn child | 
| H361 | Suspected of damaging fertility or the unborn child | 
| H361d | Suspected of damaging the unborn child | 
| H362 | May cause harm to breast-fed children | 
| H370 | Causes damage to organs | 
| H371 | May cause damage to organs | 
| H372 | Causes damage to organs through prolonged or repeated exposure | 
| H373 | May cause damage to organs through prolonged or repeated exposure | 
| Environmental hazards | |
| Code | Phrase | 
| H400 | Very toxic to aquatic life | 
| H401 | Toxic to aquatic life | 
| H402 | Harmful to aquatic life | 
| H410 | Very toxic to aquatic life with long-lasting effects | 
| H411 | Toxic to aquatic life with long-lasting effects | 
| H412 | Harmful to aquatic life with long-lasting effects | 
| H413 | May cause long-lasting harmful effects to aquatic life | 
| H420 | Harms public health and the environment by destroying ozone in the upper atmosphere | 
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL


